

ALLIGATOR BIOSCIENCE TO PARTICIPATE IN UPCOMING INDUSTRY EVENTS IN JANUARY 2023

Lund, Sweden, December 13, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following industry conferences during January 2023:

- **41st Annual J.P. Morgan Healthcare Conference, January 9 - 12, San Francisco, United States**

Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, and David Harrison, Head of Business Development at Alligator Bioscience, will be present in San Francisco during the J.P. Morgan 41st Annual Healthcare Conference to meet with investors and potential strategic partners.

- **Redeye Fight Cancer Day 2023, January 19, Stockholm**

Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.

- **Aktiespararna "Aktiedagen i Lund", January 31, Lund**

Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.

The information was submitted for publication, through the agency of the contact persons set out below, at 8:00 a.m. CET on December 13, 2022.

For further information, please contact:

Søren Bregenholt, CEO

E-mail: soren.bregenholt@alligatorbioscience.com

Phone: +46 (0) 46 540 82 00

LifeSci Advisors

Investor Relations

Guillaume van Renterghem

E-mail: gvanrenterghem@lifesciadvisors.com

Phone: +41 (0) 76 735 01 31

PRESS RELEASE

13 December 2022 08:00:00 CET



About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

[Alligator Bioscience to Participate in Upcoming Industry Events in January 2023](#)